its 12months to wait for results of the trial, however the LAD sales according to their last announcement should be beginning over the next few weeks and this will be a major price mover for the stock. I do not hold yet as I still believe their will be a little more of a retraction however their are plenty of price movers for this stock other than the cancer trial results. The following is from the announcement on 19 June.
+++++++++++++++++++++++++ Norwood Abbey Limited (ASX:NAL) has exhibited its revolutionary laser device ("LAD") for the delivery of topically applied anaesthetics at the 6 th International Symposium on Paediatric Pain Management. Over 400 delegates are attending the symposium in Sydney from 15-19 th June 2003.
Norwood has received very significant interest from, Australian, New Zealand, North American and European delegates.
"This product will revolutionize children's health care as we know it. Imagine painless blood tests and needle procedures - children may actually like going to the doctor" said Renee Manworren, Paediatric Clinical Nurse and Manager of Pain Management, at the Childrens Medical Centre of Dallas in the USA.
The Children's Medical Centre of Dallas will commence using the LAD over the next couple of months and their response to the LAD has been tremendous.
The LAD system consists of a laser device and single-use disposable tip, and is intended to painlessly and temporarily alter the outer layer of the skin (stratum corneum) enhancing the penetration of topically applied drugs. Clinicians and nurses indicate that the slow onset of action of topically applied anaesthetics is the major barrier to use of these products prior to needle insertion procedures. The LAD reduces the time of anaesthesia onset from 30-60 minutes to just 5 minutes, enabling more patients to be treated with local anaesthetic prior to cannulation, venipuncture and other needle sticks.
Norwood is commencing large-scale manufacture of LAD units with Lightmed Corporation of Taiwan. Norwood expects to commence sales in North America within weeks. Executive Chairman, Peter Hansen, said "The Company believes that the LAD technology represents a breakthrough in transdermal drug delivery of topically applied local anaesthetics. According to Mr Hansen, there is also potential to use the LAD with many other pharmaceuticals including vaccines and anti-inflammatories.
NAL Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
